Search Medical Condition
Please enter condition
Please choose location from dropdown
Clear Trial Filters

Santa Monica, California Clinical Trials

A listing of Santa Monica, California clinical trials actively recruiting patient volunteers.

RESULTS

Found (16) clinical trials

Study to Evaluate the Real-world Effectiveness of Lanadelumab in Participants With Hereditary Angioedema (HAE)

This observational, prospective study aims to evaluate the real-world effectiveness of lanadelumab in participants with hereditary angioedema (HAE). Participant-reported attack diaries and patient-reported outcomes (PROs) as well as physician assessments at standard of care (SoC) visits will be used to describe HAE attack rates, treatment patterns, healthcare utilization and participant ...

Phase N/A

1.14 miles

Learn More »

This is a randomized, placebo-controlled, double-blind, crossover study of oral BTD-001 in adults with Idiopathic Hypersomnia.  

Phase

1.14 miles

Learn More »

Platform Study for Prostate Researching Translational Endpoints Correlated to Response to Inform Use of Novel Combinations

This is an open-label, non-randomized, exploratory platform protocol designed to assess the safety and antitumor activity of multiple immunotherapy combinations in participants with mCRPC who have received prior therapy. The platform study will consist of 2 stages: Stage 1, an initial stage to evaluate safety, biomarkers, and clinical activity of ...

Phase

2.99 miles

Learn More »

BOTOX Treatment of Masseter Muscle Prominence

Based on the results of the Phase 2 Study 191622-130, the current Phase 2b study is designed to further evaluate the safety and efficacy of BOTOX for the treatment of Masseter Muscle Prominence (MMP) in adults.

Phase

2.99 miles

Learn More »

A Study of Gene Edited Autologous Neoantigen Targeted TCR T Cells With or Without Anti-PD-1 in Patients With Solid Tumors

This is a first in human, single arm, open label, Phase 1a/1b study to determine the safety, feasibility, and efficacy of a single dose of NeoTCR-P1 T cells in participants with solid tumors.

Phase

4.2 miles

Learn More »

A Phase 3 Randomized Parallel Group Study Comparing the Efficacy & Safety of SB206 & Vehicle Gel in the Treatment of MC (B-SIMPLE2)

This is a Phase 3 multi-center, randomized, double-blind, vehicle-controlled, parallel group study to be conducted in approximately 340 subjects with MC. After obtaining informed consent/assent, subjects who satisfy entry criteria will be randomized 2:1 (active:vehicle). Subjects receiving current treatment for MC at the time of the Screening Visit will enter ...

Phase

6.01 miles

Learn More »

A Study to Confirm Safety and Efficacy of BAN2401 in Participants With Early Alzheimer's Disease

This study will be conducted to evaluate the efficacy of BAN2401 in participants with early Alzheimer's disease (EAD) by determining the superiority of BAN2401 compared with placebo on the change from baseline in the Clinical Dementia Rating-Sum of Boxes (CDR-SB) at 18 months of treatment in the Core Study. This ...

Phase

6.79 miles

Learn More »

A Study to Investigate the Safety and Efficacy of ABBV-105 and Upadacitinib Given Alone or in Combination in Participants With Moderately to Severely Active Systemic Lupus Erythematosus

The main objective of this study is to evaluate the safety and efficacy of ABBV-105, upadacitinib, and ABBV-599 vs placebo for the treatment of signs and symptoms of SLE in participants with moderately to severely active SLE and to define doses for further development.

Phase

6.95 miles

Learn More »

A Study of Baricitinib in Participants With Systemic Lupus Erythematosus (SLE)

The reason for this long term study is to see how safe and effective the study drug known as baricitinib is in participants with systemic lupus erythematosus (SLE) who have completed the final treatment visit of study I4V-MC-JAHZ (NCT03616912) or study I4V-MC-JAIA (NCT03616964).

Phase

6.95 miles

Learn More »

Omega-3 Replacement With Krill Oil in Disease Management of SLE

A randomized, double-blind controlled, multicenter study in SLE patients given AKBM-3031or placebo for 24 weeks (randomized period) and followed by an open label extension (OLE) treatment with AKBM-3031 for the next 24 weeks. Patients will be maintained on stable doses of background medications, except for glucocorticoids. Decreases in doses of ...

Phase N/A

6.95 miles

Learn More »